Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5828242 | European Journal of Pharmacology | 2014 | 6 Pages |
Abstract
HMGB1-RAGE signaling pathway is involved in the development of ALI/ARDS. At the same time, activation of PPARγ has been shown to inhibit the occurrence of ALI/ARDS. However, it is unknown whether activation of PPARγ benefits ALI/ARDS by regulation of HMGB1-RAGE signaling. This study aims to address these issues. We found in this study that LPS induced dramatic pathological changes of ALI in mice; these were accompanied with elevated expression of HMGB1 and RAGE. Prior treatment of mice with PPARγ agonist rosiglitazone significantly suppressed LPS-induced ALI and reversed the elevation of HMGB1 and RAGE; these were accompanied with the induction of HO-1. The presence of selective HO-1 inhibitor Znpp abolished the protective effects of rosiglitazone on LPS-induced ALI. This study suggests that activation of PPARγ inhibits the development of LPS-induced ALI by negative modulation of HMGB1-RAGE pathway, and has a potential value in the clinical treatment of such conditions.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Guizuo Wang, Lu Liu, Yonghong Zhang, Dong Han, Jiamei Lu, Jing Xu, Xinming Xie, Yuanyuan Wu, Dexin Zhang, Rui Ke, Shaojun Li, Yanting Zhu, Wei Feng, Manxiang Li,